Detalhe da pesquisa
1.
Empagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med
; 388(2): 117-127, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36331190
2.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Lancet
; 403(10424): 379-390, 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38109916
3.
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
J Am Soc Nephrol
; 35(2): 202-215, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38082486
4.
Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease.
Am J Nephrol
; 55(2): 262-272, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37903483
5.
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.
Clin Exp Nephrol
; 28(6): 588-595, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643286
6.
Lipopolysaccharide Tolerance in Human Primary Monocytes and Polarized Macrophages.
Int J Mol Sci
; 24(15)2023 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37569572
7.
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
Circulation
; 143(4): 310-321, 2021 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33095032
8.
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
Diabetes Obes Metab
; 22(12): 2335-2347, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32744354
9.
Correction to: Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes.
BMC Nephrol
; 21(1): 200, 2020 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32466752
10.
Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes.
BMC Nephrol
; 21(1): 167, 2020 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32380961
11.
Detection of carnosinase-1 in urine of healthy individuals and patients with type 2 diabetes: correlation with albuminuria and renal function.
Amino Acids
; 51(1): 17-25, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29961141
12.
Identification and characterisation of carnostatine (SAN9812), a potent and selective carnosinase (CN1) inhibitor with in vivo activity.
Amino Acids
; 51(1): 7-16, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29922921
13.
Carnosinase concentration, activity, and CNDP1 genotype in patients with type 2 diabetes with and without nephropathy.
Amino Acids
; 51(4): 611-617, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30610469
14.
Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
Circulation
; 144(15): 1265-1267, 2021 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34397263
15.
Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals.
Diabetes Obes Metab
; 24(7): 1390-1393, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35302277
16.
Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes.
J Diabetes Complications
; 37(9): 108588, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37633072
17.
Different conformational forms of serum carnosinase detected by a newly developed sandwich ELISA for the measurements of carnosinase concentrations.
Amino Acids
; 43(1): 143-51, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22349764
18.
Analysis of eGFR index category and annual eGFR slope association with adverse clinical outcomes using real-world Japanese data: a retrospective database study.
BMJ Open
; 12(2): e052246, 2022 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35197338
19.
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.
Diabetes Care
; 45(6): 1445-1452, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35472672
20.
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.
Eur J Heart Fail
; 24(10): 1829-1839, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35711093